Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp Sells 11,250 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Alnylam Pharmaceuticals Trading Up 1.2 %

Shares of Alnylam Pharmaceuticals stock traded up $3.22 on Friday, hitting $278.76. 915,753 shares of the company’s stock traded hands, compared to its average volume of 699,931. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm’s 50-day moving average price is $246.27 and its two-hundred day moving average price is $260.10. The stock has a market capitalization of $35.95 billion, a PE ratio of -106.40 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the business posted $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALNY. Piper Sandler restated an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Bank of America increased their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $298.61.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Huntington National Bank lifted its position in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals during the third quarter worth about $42,000. Finally, True Wealth Design LLC grew its stake in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.